News
BioXcel's agitation drug gets FDA Fast Track
The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer's and schizo
